Vaxcyte (PCVX) Accounts Payables (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Accounts Payables data on file, last reported at $63.1 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 207.4% year-over-year to $63.1 million in Q1 2026; TTM through Mar 2026 was $63.1 million, a 207.4% increase from a year earlier, with the FY2025 full-year figure at $70.9 million, up 46.34% from the prior year.
• Accounts Payables for Q1 2026 stood at $63.1 million, down from $70.9 million in the prior quarter.
• Over the last five years, Accounts Payables for PCVX reached as high as $70.9 million in Q4 2025 and fell as low as $4.8 million in Q1 2022.
• Historically, Accounts Payables has averaged $24.6 million across 5 years, with a median of $16.3 million in 2023.
• Across the five-year window, Accounts Payables sank 84.93% in 2022 and surged 232.16% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $9.8 million in 2022, then jumped by 48.92% to $14.6 million in 2023, then jumped by 232.16% to $48.5 million in 2024, then soared by 46.34% to $70.9 million in 2025, then decreased by 11.06% to $63.1 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $63.1 million in Q1 2026, $70.9 million in Q4 2025, and $49.0 million in Q3 2025.